Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MediBIC and Kobe University Hospital to Jointly Form Conference on Pharmacogenomics
April 17, 2012
- JCSOA to Draw Up Guideline for Coping with Business Conflicts this Year
April 17, 2012
- Actelion Receives Approval for NPC Treatment
April 17, 2012
- Ajinomoto Pharmaceuticals to Distribute Lentinan from July: Ajinomoto, Taiho
April 17, 2012
- Generic Names Used in 25% of Prescriptions Issued by GPs: Nihon Chouzai
April 17, 2012
- National, Rosai Hospitals to Buy 9,000 Products in First Joint Purchasing, HQ to Buy Generics by Bulk
April 16, 2012
- Elmed Eisai Found to Make Good Impression on Pharmacists: Survey
April 16, 2012
- Over 60% of Drug Makers Increased Hiring of New Graduates in 2012: Jiho Survey
April 16, 2012
- Ain Pharmaciez to Introduce Electronic Drug Notebooks at All Its Group Stores in July
April 16, 2012
- Takeda to Acquire URL Pharma, Boost US Business Base Through Field of Gout
April 13, 2012
- ECI to Initiate Clinical Research for Cancer Therapy ECI301
April 13, 2012
- AnGes MG to Codevelop High Blood Pressure Treatment Oral Vaccine with Korean Company
April 13, 2012
- US Subsidiary’s CEO Resigns: DSP
April 13, 2012
- AnGes MG Obtains Pharmaceutical Use Patent in Japan for NF-κB Decoy Oligo
April 13, 2012
- Pfizer Focuses on Personalized Medicine for Oncology Area with Xalkori
April 12, 2012
- Teijin Pharma to Expand Overseas Marketing of Febuxostat in 117 Countries
April 12, 2012
- Taiho’s TS-1 Launched in UK, Approved in Hong Kong
April 12, 2012
- Toyota Tsusho Signs Agreement with Korean Venture to Become Sole Agent in Japan
April 12, 2012
- Sanofi Pasteur Targets Double Sales in Japan, Enters 4 Products Including IPV
April 11, 2012
- Takeda Pharmaceutical to Be Refunded 57.1 Bil. Yen for Transfer Pricing Taxation
April 11, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…